Collaboration and teamwork are integral to Medicago’s success

The clinical and technological advances we have made are, in large part, due to the close and lasting partnerships that Medicago’s team has fostered over the years.

We are a trusted partner of health authorities around the globe. We have partnered with US governmental agencies, DARPA and BARDA.  The Canadian government has provided significant funding for the development of our COVID-19 vaccine candidate and the construction of our new large-scale manufacturing facility in Quebec, Canada.

We have worked with governmental agencies in Europe and Latin America to conduct clinical trials.

Our broad network of prestigious partners also spans across industry and academia – including Harvard University and Stanford University. We have also partnered with GSK to leverage its proven adjuvant technology in the development of our COVID-19 vaccine candidate. These partnerships are a testament to our track record of innovative research and development and underscore the immense promise of our technology.